Clinical trial / 2021
Oral semaglutide reduced daily ad libitum energy intake, improved appetite control, and decreased body weight and fat mass in people with type 2 diabetes.
A randomized, double-blind, placebo-controlled crossover trial evaluated 12 weeks of once-daily oral semaglutide versus placebo in 15 subjects with type 2 diabetes. In 13 evaluable subjects, total daily ad libitum energy intake was significantly lower by 38.9% with oral semaglutide versus placebo (estimated treatment difference: -5096.0 kJ; 95% CI -7000.0, -3192.1; P = .0001). Satiety, hunger, and overall appetite scores significantly favored semaglutide after a fat-rich breakfast, alongside fewer food cravings and better eating control. Mean body weight decreased by 2.7 kg with oral semaglutide compared to 0.1 kg with placebo, primarily due to loss of body fat mass.
- Study type
- Randomized, double-blind, placebo-controlled crossover trial
- Who was studied
- 15 subjects with type 2 diabetes (13 evaluable)
- What was measured
- Ad libitum energy intake, appetite ratings, eating/craving control, and body weight/composition
THE PAPER
Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes.
Gibbons C, Blundell J, Tetens Hoff S, Dahl K, Bauer R, Baekdal T. Diabetes Obes Metab, 2021.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.